BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8406417)

  • 1. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues.
    Colgan TJ; Pendergast S; LeBlanc M
    Hum Pathol; 1993 Oct; 24(10):1073-7. PubMed ID: 8406417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological changes of uterine leiomyomas after GnRH agonist therapy.
    Grigoriadis C; Papaconstantinou E; Mellou A; Hassiakos D; Liapis A; Kondi-Pafiti A
    Clin Exp Obstet Gynecol; 2012; 39(2):191-4. PubMed ID: 22905461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents].
    Resta L; Sanguedolce F; Orsini G; Laricchia L; Piscitelli D; Fiore MG
    Pathologica; 2004 Apr; 96(2):35-41. PubMed ID: 15449444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GnRH analogue-induced uterine shrinkage enabling a vaginal hysterectomy and repair in large leiomyomatous uteri.
    Schneider D; Golan A; Bukovsky I; Pansky M; Caspi E
    Obstet Gynecol; 1991 Sep; 78(3 Pt 2):540-1. PubMed ID: 1831252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas.
    Stovall TG; Ling FW; Henry LC; Woodruff MR
    Am J Obstet Gynecol; 1991 Jun; 164(6 Pt 1):1420-3; discussion 1423-5. PubMed ID: 1904681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
    Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
    Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
    Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
    Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas.
    Yoshida M; Ohtsuru A; Samejima T; Okazaki M; Fujishita A; Ito M; Yamashita S; Ishimaru T
    Endocr J; 1999 Feb; 46(1):81-90. PubMed ID: 10426571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
    Friedman AJ; Lobel SM; Rein MS; Barbieri RL
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preoperative treatment with GnRH analogs in hysterectomy].
    Serrao L; Brizzi C; Primiero FM
    Clin Ter; 1994 Nov; 145(11):403-6. PubMed ID: 7889725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GnRH agonists before surgery for uterine leiomyomas. A review.
    Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
    J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of uterine fibroids with GnRH-analogues prior to hysterectomy.
    Stjernquist M
    Acta Obstet Gynecol Scand Suppl; 1997; 164():94-7. PubMed ID: 9225649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy.
    Khurana KK; Singh SB; Tatum AH; Schulz V; Badawy SZ
    J Reprod Med; 1999 Jun; 44(6):487-92. PubMed ID: 10394541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
    Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
    Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
    Lethaby A; Vollenhoven B; Sowter M
    Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
    Lethaby A; Vollenhoven B; Sowter M
    Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal therapy before surgical treatment for uterine leiomyomas.
    Moghissi KS
    Surg Gynecol Obstet; 1991 Jun; 172(6):497-502. PubMed ID: 1827931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
    Takahashi K; Kawamura N; Ishiko O; Ogita S
    Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of uterine leiomyomas.
    Vilos GA; Allaire C; Laberge PY; Leyland N;
    J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix.
    Flierman PA; Oberyé JJ; van der Hulst VP; de Blok S
    BJOG; 2005 May; 112(5):638-42. PubMed ID: 15842290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.